Jounce Therapeutics, Inc.
(NASDAQ : JNCE)

( )
JNCE After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
BIIBBiogen Inc.
-0.24%343.281.2%$589.37m
GILDGilead Sciences, Inc.
1.33%73.320.9%$534.10m
CELGCelgene Corporation
0.35%91.201.2%$502.04m
AMGNAmgen Inc.
-0.13%197.311.2%$470.98m
ILMNIllumina, Inc.
1.67%331.443.5%$390.25m
REGNRegeneron Pharmaceuticals, Inc.
1.00%378.562.6%$309.76m
VRTXVertex Pharmaceuticals Incorporated
0.65%176.861.9%$202.70m
ALXNAlexion Pharmaceuticals, Inc.
0.71%116.992.0%$186.49m
AAgilent Technologies, Inc.
0.75%64.951.5%$163.20m
SRPTSarepta Therapeutics, Inc.
1.18%129.1416.6%$139.77m
NKTRNektar Therapeutics
2.24%61.965.6%$128.47m
EXASExact Sciences Corporation
1.71%50.0525.3%$122.85m
BLUEBluebird Bio, Inc.
0.06%158.8014.6%$120.19m
BMRNBioMarin Pharmaceutical Inc.
0.72%99.744.4%$119.07m
INCYIncyte Corporation
0.83%69.622.5%$116.18m

Company Profile

Jounce Therapeutics, Inc. is a clinical stage immunotherapy company, which treat catcer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients. Its products pipeline include JTX-2011 (ICOS); JTX-4014 (PD-1); Lead Macrophage Program; Macrophage Targeting; T Reg; B Cells; and Stromal Targeting. The company was founded by Louis M. Weiner, Drew M. Pardoll, Thomas F. Gajewski, James P. Allison, Robert Schreiber, and Padmanee Sharmain in 2013 and is headquartered in Cambridge, MA.